- ORIC Pharmaceuticals (ORIC) stock is rising on a collaboration agreement with Pfizer (PFE).
- That will see them work together on a Phase 2 clinical trial of their multiple myeloma treatments.
- It also has PFE acquiring $25 million worth of ORIC stock.
The big news here is ORIC Pharmaceuticals and Pfizer working together on the development of ORIC-533. This is a treatment in development for multiple myeloma with Pfizer agreeing to help with a planned Phase 2 clinical trial.
Read full report in Investorplace